

25 November 2009

Aqua Bounty Technologies, Inc.
(“Aqua Bounty” or “the Company”)

Operations Update

Aqua Bounty Technologies, Inc. (AIM: ABTX), a biotechnology company focused on enhancing productivity in the aquaculture market, today reports an update on the Company's regulatory progress, operations and outlook for current fiscal year.

In its interim results in September this year, the Company reported that it had completed its submission of all remaining studies for its FDA application for AquaAdvantage[®] Salmon (AAS) and that it expected the FDA to complete its internal review by the end of the year. Although there has been considerable progress, it is likely that this process will extend into next year. Management understands that it is the highly novel nature of the product that has extended the timescale and not the emergence of any regulatory difficulty. The Company remains confident that the process will complete within the next few months and that it will then be able to commence commercialization.

Plans are in hand to begin supplying AAS egg samples to the first commercial producers for field trials as soon as FDA approval has been received. This will be followed by the sale of a larger production of eggs from the 2010 spawning season in Q1 2011. Separately, the project to produce AAS for a commercial market test is proceeding on plan and the first salmon are expected to be harvested and ready for sale when they reach market weight between March and May of 2010.

The Company continues to meet its targets for spending and cash use and expects to end 2009 with total cash use for the year at under \$5 million as previously indicated.

For further information, please contact:

Aqua Bounty Technologies
David Frank

+1 781 899 7755

Nomura Code
Richard Potts / Giles Balleny

+44 (0) 20 7776 1200

Bell Pottinger Corporate & Financial
Daniel de Belder / Samantha Boston

+44 (0) 20 7861 3232